Donald C. Carpenter

SB 239063, a Potent p38 MAP Kinase Inhibitor, Reduces Inflammatory Cytokine Production, Airways Eosinophil Infiltration, and Persistence

David C. Underwood, Ruth R. Osborn, Charles J. Kotzer et al. · Journal of Pharmacology and Experimental Therapeutics · 2000 · 244 citations

Medicine, Immunology, Pharmacology +15

The pharmacokinetics and pharmacodynamics of danirixin (GSK1325756) − a selective CXCR2 antagonist − in healthy adult subjects

Bruce E. Miller, Sunil Mistry, Kevin Smart et al. · BMC Pharmacology and Toxicology · 2015 · 64 citations · Full text

Medicine, Clinical Pharmacokinetics, Pharmacology +16

A novel flow cytometric assay of human whole blood neutrophil and monocyte CD11b levels: Upregulation by chemokines is related to receptor expression, comparison with neutrophil shape change, and effects of a chemokine receptor (CXCR2) antagonist

Grant C. Nicholson, Rachel Tennant, Donald C. Carpenter et al. · Pulmonary Pharmacology & Therapeutics · 2006 · 55 citations

Life Sciences, Cell Biology, Immunology +16

Epithelial desquamation observed in a phase I study of an oral cathepsin C inhibitor (GSK2793660)

Bruce E. Miller, Ruth J. Mayer, Navin Goyal et al. · British Journal of Clinical Pharmacology · 2017 · 55 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +13

Danirixin: A Reversible and Selective Antagonist of the CXC Chemokine Receptor 2

Jakob Busch‐Petersen, Donald C. Carpenter, Miriam Burman et al. · Journal of Pharmacology and Experimental Therapeutics · 2017 · 47 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16